Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2017-02-14 Regulatory Filings
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings
2017-02-14 English
SC 13G/A
Major Shareholding Notification
2017-02-14 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-14 English
SC 13G/A
Major Shareholding Notification
2017-02-13 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-10 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from Ligand Pharmaceuticals to the SEC responding to a Staff comment letter regarding a previously filed Form 8-K dated November 3, 2016. The content focuses on detailed accounting analysis and disclosures related to the gain on deconsolidation of Viking Therapeutics, non-GAAP adjustments, and tax rate impacts to be included in the next earnings release. It references ASC accounting standards and provides management's responses to SEC comments. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a regulatory correspondence responding to SEC inquiries about accounting treatments and disclosures related to a prior filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and compliance documents that do not fit other specific categories.
2017-02-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.